@article{727ee39398f84c1cbb7b44ec4617f9d6,
title = "HIV-1 drug resistance and genetic diversity in a cohort of people with HIV-1 in Nigeria",
abstract = "Objective:This study was designed to provide information on the genetic diversity of HIV-1 and drug resistance mutations in Nigeria, as there is limited understanding of variants circulating in the country.Methods:We used an advanced next-generation sequencing platform, Primer ID, to: Investigate the presence of high and low abundance drug resistance mutations; characterize preexisting Integrase Strand Transfer Inhibitor (INSTI) mutations in antiretroviral therapy (ART)-experienced but dolutegravir-naive individuals; detect recent HIV-1 infections and characterize subtype diversity from a cohort of people with HIV-1 (PWH).Results:HIV-1 subtype analysis revealed the predominance of CRF02_AG and subtype G in our study population. At detection sensitivity of 30% abundance, drug resistance mutations (DRMs) were identified in 3% of samples. At a sensitivity level of 10%, DRMs were identified in 27.3% of samples. We did not detect any major INSTI mutation associated with dolutegravir-resistance. Only one recent infection was detected in our study population.Conclusion:Our study suggests that dolutegravir-containing antiretroviral regimens will be effective in Nigeria. Our study also further emphasizes the high genetic diversity of HIV-1 in Nigeria and that CRF02_AG and subtype G are the dominant circulating forms of HIV-1 in Nigeria. These two circulating forms of the virus are largely driving the epidemic in the country.",
keywords = "Dolutegravir, Drug resistance, HIV-1, Primer ID, Subtype",
author = "Oluniyi, {Paul E.} and Ajogbasile, {Fehintola V.} and Shuntai Zhou and Iyanuoluwa Fred-Akintunwa and Polyak, {Christina S.} and Ake, {Julie A.} and Sodsai Tovanabutra and Michael Iroezindu and Morgane Rolland and Happi, {Christian T.}",
note = "Funding Information: This work is made possible by support from Flu Lab and a cohort of generous donors through TED's Audacious Project, including the ELMA Foundation, MacKenzie Scott, the Skoll Foundation, and Open Philanthropy. This work was also supported by grants from the National Institute of Allergy and Infectious Diseases ( https://www.niaid.nih.gov ), NIH-H3Africa ( https://h3africa.org ) (U01HG007480 and U54HG007480 to C.T.H.), the World Bank grant (worldbank.org) (ACE IMPACT project to C.T.H.), the President's Emergency Plan for AIDS Relief via a cooperative agreement between the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and the U.S. Department of Defense (W81XWH-18–2–0040 to J.A.A.). The views expressed are those of the authors and should not be construed to represent the positions of the US Army, the Department of Defense, or the Department of Health and Human Services. Funding Information: Funding: This work is made possible by support from Flu Lab and a cohort of generous donors through TED's Audacious Project, including the ELMA Foundation, MacKenzie Scott, the Skoll Foundation, and Open Philanthropy. This work was also supported by grants from the National Institute of Allergy and Infectious Diseases ( https://www.niaid.nih.gov ), NIH-H3Africa ( https://h3africa.org ) (U01HG007480 and U54HG007480 to C.T.H.), the World Bank grant (worldbank.org) (ACE IMPACT project to C.T.H.), the President's Emergency Plan for AIDS Relief via a cooperative agreement between the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and the US Department of Defense (W81XWH-18-2-0040 to J.A.A.). Publisher Copyright: {\textcopyright} 2022 Lippincott Williams and Wilkins. All rights reserved.",
year = "2022",
month = jan,
day = "1",
doi = "10.1097/QAD.0000000000003098",
language = "English",
volume = "36",
pages = "137--146",
journal = "AIDS",
issn = "0269-9370",
number = "1",
}